DelveInsight’s, “Renal Cell Carcinoma Pipeline Insight 2023” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Renal Cell Carcinoma pipeline landscape. It covers the Renal Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Renal Cell Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Renal Cell Carcinoma Pipeline Report

• DelveInsight’s Renal Cell Carcinoma pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Renal Cell Carcinoma treatment.
• The leading companies working in the Renal Cell Carcinoma Market include AstraZeneca, Infinity Pharmaceuticals, Ipsen, Novartis, Aveao pharmaceuticals, Merck Sharp & Dohme Corp., Pfizer, Bayer Healthcare, Incyte Corporation, GlaxoSmithKline, Bristol-Myers Squibb, Hoffman La Roche, Amgen, ColImmune, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Betta Pharmaceuticals, Regeneron Pharmaceuticals, Cemiplimab, Aravivie Inc., X4 pharmaceuticals, and others.
• Promising Renal Cell Carcinoma Pipeline Therapies in the various stages of development include Pexastimogene Devacirepvec (Pexa-Vec), Cemiplimab, lenvatinib, everolimus, and others.
• November 2023: AVEO Pharmaceuticals Inc. announced a study of Phase 3 clinical trials for Tivozanib and Nivolumab. This study will be comparing tivozanib in combination with nivolumab to tivozanib alone in subjects with advanced Renal Cell Carcinoma (RCC) who have had 1 or 2 prior lines of therapy, one of which was an Immune Checkpoint Inhibitor (ICI).
• November 2023: Bristol-Myers Squibb announced a study of Phase 3 clinical trials for Nivolumab and Ipilimumab. The purpose of this study is to compare the objective response rate, progression free survival and the overall survival of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated Renal Cell Cancer.

 

Request a sample and discover the recent advances in Renal Cell Carcinoma Treatment Drugs @ Renal Cell Carcinoma Pipeline Report

 

In the Renal Cell Carcinoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Renal Cell Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Renal Cell Carcinoma Overview

Renal cell carcinoma (RCC) is also called hypernephroma, renal adenocarcinoma, or renal or kidney cancer. Renal cell cancer is a disease in which malignant (cancer) cells form in tubules of the kidney. In early stages Renal carcinoma is symptom free but as the diseases progresses the symptoms may include: lump in the abdomen, fatigue, and unexplained weight loss, blood in the urine, loss of appetite, vision problem, and excessive hair growth.

 

Find out more about Renal Cell Carcinoma Treatment Landscape @ Drugs for Renal Cell Carcinoma Treatment

 

Renal Cell Carcinoma Emerging Drugs Profile

• CM082: Betta Pharmaceuticals
• TQB 2450: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• IPI-549: Infinity Pharmaceuticals
• CMN-001: ColImmune

 

Renal Cell Carcinoma Pipeline Therapeutics Assessment

There are approx. 30+ key companies which are developing the therapies for Renal Cell Carcinoma. The Renal Cell Carcinoma companies which have their Renal Cell Carcinoma drug candidates in the most advanced stage, i.e. phase III include, Betta Pharmaceuticals.

 

DelveInsight’s Renal Cell Carcinoma pipeline report covers around 30+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Subcutaneous
• Intravenous
• Intramuscular
• Molecule Type

 

Products have been categorized under various Molecule types such as

• Bispecific Antibody
• Peptides
• Small molecule
• Gene therapy
• Product Type

 

Learn more about the emerging Renal Cell Carcinoma Pipeline Therapies @ Renal Cell Carcinoma Clinical Trials Assessment

 

Scope of the Renal Cell Carcinoma Pipeline Report

• Coverage- Global
• Renal Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Renal Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Renal Cell Carcinoma Companies- AstraZeneca, Infinity Pharmaceuticals, Ipsen, Novartis, Aveao pharmaceuticals, Merck Sharp & Dohme Corp., Pfizer, Bayer Healthcare, Incyte Corporation, GlaxoSmithKline, Bristol-Myers Squibb, Hoffman La Roche, Amgen, ColImmune, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Betta Pharmaceuticals, Regeneron Pharmaceuticals, Cemiplimab, Aravivie Inc., X4 pharmaceuticals, and others.
• Renal Cell Carcinoma Pipeline Therapies- Pexastimogene Devacirepvec (Pexa-Vec), Cemiplimab, lenvatinib, everolimus, and others.

 

Dive deep into rich insights for new drugs for Renal Cell Carcinoma treatment, Visit @ Renal Cell Carcinoma Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Renal Cell Carcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Renal Cell Carcinoma – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Renal Cell Carcinoma Collaboration Deals
9. Late Stage Products (Phase III)
10. TQB 2450: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. IPI-549: Infinity Pharmaceuticals
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. AVB-S6-500: Aravive Inc.
17. Drug profiles in the detailed report…..
18. Preclinical Stage Products
19. Drug Name: Company name
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Renal Cell Carcinoma Key Companies
23. Renal Cell Carcinoma Key Products
24. Renal Cell Carcinoma – Unmet Needs
25. Renal Cell Carcinoma – Market Drivers and Barriers
26. Renal Cell Carcinoma – Future Perspectives and Conclusion
27. Renal Cell Carcinoma Analyst Views
28. Renal Cell Carcinoma Key Companies
29. Appendix

 

For further information on the Renal Cell Carcinoma pipeline therapeutics, reach out @ Renal Cell Carcinoma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/radiation-induced-esophagitis-market-forecast